NewsBenzinga캐너코드 제뉴이티, 캔델 테라퓨틱스 투자의견 ‘매수’ 유지···목표주가 13달러로 하향 캐너코드 제뉴이티, 캔델 테라퓨틱스 투자의견 ‘매수’ 유지···목표주가 13달러로 하향 Benzinga 2026.11.13 13:38 (GMT+0) Open on Benzinga Other news Canaccord Genuity Maintains Buy on Belite Bio, Raises Price Target to $314 Applied Optoelectronics Stock Sinks Amid AI Outlook Fears Canaccord Genuity Maintains Buy on Enovix, Lowers Price Target to $2.5 Canaccord Genuity Maintains Buy on Intuitive Machines, Lowers Price Target to $38 'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report Canaccord Genuity Maintains Buy on Nektar Therapeutics, Lowers Price Target to $149
'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report